Lyell Immunopharma Statistics
Total Valuation
LYEL has a market cap or net worth of $550.66 million. The enterprise value is $71.25 million.
| Market Cap | 550.66M |
| Enterprise Value | 71.25M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LYEL has 254.94 million shares outstanding. The number of shares has increased by 1.58% in one year.
| Shares Outstanding | 254.94M |
| Shares Change (YoY) | +1.58% |
| Shares Change (QoQ) | +0.59% |
| Owned by Insiders (%) | 15.54% |
| Owned by Institutions (%) | 72.70% |
| Float | 163.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,314.32 |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 548.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.07, with a Debt / Equity ratio of 0.09.
| Current Ratio | 16.07 |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.70% and return on invested capital (ROIC) is -34.70%.
| Return on Equity (ROE) | -32.70% |
| Return on Assets (ROA) | -28.80% |
| Return on Capital (ROIC) | -34.70% |
| Revenue Per Employee | $580 |
| Profits Per Employee | -$1.05M |
| Employee Count | 224 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.99% in the last 52 weeks. The beta is -0.56, so LYEL's price volatility has been lower than the market average.
| Beta (1Y) | -0.56 |
| 52-Week Price Change | +13.99% |
| 50-Day Moving Average | 2.31 |
| 200-Day Moving Average | 2.10 |
| Relative Strength Index (RSI) | 46.55 |
| Average Volume (30 Days) | 918,337 |
Short Selling Information
The latest short interest is 18.23 million, so 7.15% of the outstanding shares have been sold short.
| Short Interest | 18.23M |
| Short Previous Month | 18.10M |
| Short % of Shares Out | 7.15% |
| Short % of Float | 11.14% |
| Short Ratio (days to cover) | 18.38 |
Income Statement
In the last 12 months, LYEL had revenue of $130,000 and -$234.63 million in losses. Loss per share was -$0.93.
| Revenue | 130,000 |
| Gross Profit | 130,000 |
| Operating Income | -247.01M |
| Pretax Income | -234.63M |
| Net Income | -234.63M |
| EBITDA | -214.38M |
| EBIT | -234.63M |
| Loss Per Share | -$0.93 |
Balance Sheet
The company has $546.51 million in cash and $56.89 million in debt, giving a net cash position of $489.61 million or $1.92 per share.
| Cash & Cash Equivalents | 546.51M |
| Total Debt | 56.89M |
| Net Cash | 489.61M |
| Net Cash Per Share | $1.92 |
| Equity / Book Value | 654.95M |
| Book Value Per Share | 2.57 |
| Working Capital | 520.17M |
Cash Flow
In the last 12 months, operating cash flow was -$163.69 million and capital expenditures -$2.69 million, giving a free cash flow of -$166.38 million.
| Operating Cash Flow | -163.69M |
| Capital Expenditures | -2.69M |
| Free Cash Flow | -166.38M |
| FCF Per Share | -$0.66 |
Margins
Gross margin is 100.00%, with operating and profit margins of -190,006.15% and -180,486.15%.
| Gross Margin | 100.00% |
| Operating Margin | -190,006.15% |
| Pretax Margin | -180,486.15% |
| Profit Margin | -180,486.15% |
| EBITDA Margin | -164,909.23% |
| EBIT Margin | -180,486.15% |
| FCF Margin | -127,984.62% |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.58% |
| Shareholder Yield | -1.58% |
| Earnings Yield | -41.83% |
| FCF Yield | -29.67% |
Analyst Forecast
The average price target for LYEL is $5.50, which is 154.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.50 |
| Price Target Difference | 154.04% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LYEL has an Altman Z-Score of 1.47 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.47 |
| Piotroski F-Score | 2 |